Oksana Koneva

Armenia grants first authorization for Agenus BOT plus BAL therapy in MSS mCRC

Armenia grants first authorization for Agenus BOT plus BAL therapy in MSS mCRC
Agenus wins Armenia BOT plus BAL nod

Agenus announced that Armenia has granted its first marketing authorizations for BOT plus BAL in adults with previously treated microsatellite stable metastatic colorectal cancer (MSS mCRC) without active liver metastases.

The regulatory milestone marks a notable expansion for Agenus's oncology portfolio and access in the region. Further details regarding the commercial rollout or patient access have not been disclosed.

Agenus previously shared an update on the execution of its ROBBIN Phase 3 trial and the BOT+BAL immunotherapy strategy in colorectal cancer, according to company disclosures. In separate developments, the firm reported 48 percent three-year overall survival in a Phase 1b ovarian cancer study, matching year-two results, as detailed in recent follow-up data. These milestones continue to inform Agenus’s expansion in oncology indications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.